Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 11/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101580 | 0.88 | CYP1A2 (0.45) | CYP1A2CYP2D6MAT2APRMT5NTRK1 | |
| SCHEMBL5101582 | 0.80 | MAT2A (0.39) | TACR1MAT2AMTNR1AMTNR1BPRMT5 | |
| SCHEMBL5094657 | 0.76 | MAT2A (0.38) | TACR1CYP1A2MAT2A | |
| SCHEMBL5101581 | 0.75 | NTRK1 (0.40) | CYP1A2MAT2APRMT5MAPK8MAPK9 | |
| SCHEMBL5089907 | 0.75 | HTR6 (0.44) | TACR1CYP1A2CYP2D6MAT2AMTNR1A | |
| SCHEMBL5101584 | 0.71 | NTRK1 (0.40) | CYP1A2MAT2APRMT5MAPK8MAPK9 | |
| SCHEMBL5094719 | 0.69 | TACR1 (0.52) | TACR1 | |
| SCHEMBL5095637 | 0.69 | HTR6 (0.57) | TACR1 | |
| SCHEMBL6193055 | 0.69 | PDE10A (0.40) | TACR1CYP1A2MAT2A | |
| SCHEMBL28888717 | 0.68 | MAT2A (0.41) | TACR1CYP1A2MAT2AMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250834-A1 | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-11-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250834-A1 | Novel tetracyclic arylcarbonyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical composition containing them | TPH1, HTR1A, HTR5A | TACR1 74/4885CYP1A2 277/4885CYP2D6 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.